Edward Pershing - 03 Oct 2023 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
Director
Signature
/s/ Edward Pershing
Issuer symbol
PVCT
Transactions as of
03 Oct 2023
Transactions value $
$5,268
Form type
4
Filing time
19 Oct 2023, 17:16:19 UTC
Previous filing
04 Aug 2023
Next filing
27 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT Series D-1 Convertible Preferred Stock Purchase $55.3K +19.3K +2.88% $2.86* 691K 03 Oct 2023 Common Stock 193K Direct F1, F2, F3
transaction PVCT 8% Unsecured Convertible Promissory Note Options Exercise -$50K $1.97M 14 Oct 2023 Series D-1 Convertible Preferred Stock 18.9K $2.86 Direct F4, F5
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +18.9K +2.73% $0.00 710K 14 Oct 2023 Common Stock 189K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired 19,311 shares of Series D-1 Preferred Stock in a private transaction for $55,267.
F2 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F3 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F4 The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing.
F5 On October 14, 2023, the 2022 Note was converted into 18,888 shares of Series D-1 Preferred Stock.